HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $180 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Axsome Therapeutics, maintaining a price target of $180. This suggests confidence in the company's future performance.
September 05, 2024 | 11:49 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Axsome Therapeutics, maintaining a price target of $180. This suggests confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a high price target by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100